Breaking News
Subscribe Now 0
Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 place See list
Close

Pfizer Inc (PFE_KZ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
29.00 -0.69    -2.32%
10:22:00 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  Kazakhstan
ISIN:  US7170811035 
  • Volume: 202
  • Bid/Ask: 29.03 / 29.32
  • Day's Range: 28.96 - 30.00
Pfizer 29.00 -0.69 -2.32%

NYSE:PFE_KZ Financials

 
A brief overview of the NYSE:PFE financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Pfizer over time.

Pfizer Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 1,910 million compared to USD 2,217 million a year ago. Revenue was USD 14,249 million compared to USD 24,290 million a year ago. Net loss was USD 3,369 million compared to net income of USD 4,995 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to basic earnings per share from continuing operations of USD 0.89 a year ago. Diluted loss per share from continuing operations was USD 0.59 compared to diluted earnings per share from continuing operations of USD 0.87 a year ago. Basic loss per share was USD 0.6 compared to basic earnings per share of USD 0.89 a year ago. Diluted loss per share was USD 0.6 compared to diluted earnings per share of USD 0.87 a year ago.For the full year, revenue was USD 58,496 million compared to USD 100,330 million a year ago. Net income was USD 2,119 million compared to USD 31,372 million a year ago. Basic earnings per share from continuing operations was USD 0.38 compared to USD 5.59 a year ago. Diluted earnings per share from continuing operations was USD 0.37 compared to USD 5.47 a year ago. Basic earnings per share was USD 0.38 compared to USD 5.59 a year ago. Diluted earnings per share was USD 0.37 compared to USD 5.47 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

PFE_KZ Income Statement

Gross margin TTM 60.16%
Operating margin TTM 5.95%
Net Profit margin TTM -4.7%
Return on Investment TTM 1.75%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Oct 01, 2023 Jul 02, 2023 Apr 02, 2023
Total Revenue 14249 13232 12734 18282
Gross Profit 6984 9927 9802 13535
Operating Income -1219 2954 2657 6662
Net Income -3369 -2382 2327 5543

PFE_KZ Balance Sheet

Quick Ratio MRQ 0.42
Current Ratio MRQ 0.86
LT Debt to Equity MRQ 66%
Total Debt to Equity MRQ 79.66%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Oct 01, 2023 Jul 02, 2023 Apr 02, 2023
Total Assets 215021 220168 195617
Total Liabilities 117817 120875 94381
Total Equity 97204 97204 99293 101236

PFE_KZ Cash Flow Statement

Cash Flow/Share TTM 1.41
Revenue/Share TTM 9.74
Operating Cash Flow  -
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Oct 01, 2023 Jul 02, 2023 Apr 02, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -1208 1212
Cash From Investing Activities -25485 3315
Cash From Financing Activities 27174 -2771
Net Change in Cash 475 1754
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PFE Comments

Write your thoughts about Pfizer Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
shortseller Best
shortseller Best Sep 01, 2024 7:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
People like to short more Pfizer because they know it will be difficult for the CEO to lead Pfizer to higher levels. Pfizer's stock price also hasn't moved higher since Chief Executive Albert Bourla took control of the company. thumbs 👇
Mo Ali
Av8er31 Sep 01, 2024 7:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
because they are not a growth company at the moment. but a dividend play rath
Shawn Aslani
Shawn Aslani Aug 27, 2024 11:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This what happens to PFE when a veterinarian manages a hundred plus years old company
shortseller Best
shortseller Best Aug 20, 2024 7:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
so many people short Pfizer. that is the easiest way to make money.
George Galloway
George Galloway Aug 08, 2024 3:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A few positive days and now back to normal.
Aket Orem
Aket Orem Jul 30, 2024 10:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is crazy i’m buyin more
Egbu Victor
Egbu Victor Jul 30, 2024 9:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
We are heading to $33.21 🤑🤑🤑
Aa Ro
Aa Ro Jul 30, 2024 9:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
when and why, pls?
Egbu Victor
Egbu Victor Jul 30, 2024 9:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
PFT to the moon 🤑🤑🤑🤑
shortseller Best
shortseller Best Jul 30, 2024 8:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good news = short sale. 28 is coming....
Péter Dovák
Péter Dovák Jul 30, 2024 6:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Egbu Victor
Egbu Victor Jul 26, 2024 12:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Strong Buy! +$50 coming soon
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email